Methods We conducted a prospective, single-arm, single-center, primitive study to verify the
efficacy of a 10-day tegoprazan-based (50-mg dose) concomitant therapy, including …

있다. 국내에서 시행된 다기관 무작위배정 임상시험에서 tegoprazan 과 lansoprazole 기반
제균요법 7 일의 제균율을 비교하였고 그 결과 tegoprazan 이 lansoprazole 에 비하여 …

Abstract Background and Aim Potassium‐competitive acid blockers (P‐CABs) can be used
to eradicate Helicobacter pylori infection. We aimed to evaluate the impact of treatment …

Tegoprazan, a novel potassium-competitive acid blocker, is currently available for the
treatment of Helicobacter pylori infection. We compared the efficacies of tegoprazan-based …

Objectives Tegoprazan, a novel potassium-competitive acid blocker with rapid and effective
antisecretory activity, was approved for the treatment of Helicobacter pylori infections in …

Gut and Liver, Vol. 16, No. 4, July 2022 494 www. gutnliver. org clarithromycin-resistant
group and CYP2C19 extensive metabolizers. In their study, however, Choi et al. 4 did not …

Background Potassium‐competitive acid blockers have demonstrated enormous potential in
the eradication treatment of Helicobacter pylori infection, with tegoprazan being one of the …

Methods: A total of 236 patients newly diagnosed with H. pylori were enrolled in this multi-
center, prospective, open-label, and randomized controlled study. Patients randomly …

Methods: We retrospectively reviewed the data of patients with H. pylori infection treated with
a 14-day tegoprazan-based triple therapy or 14-day esomeprazole/sodium bicarbonate …

Methods We retrospectively reviewed data from patients who received first-line treatment for
H. pylori infection using tegoprazan-or rabeprazole-based triple therapy for 2 weeks (50 mg …